BiotechTube

Abrocitinib

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Eczema

Conditions

Eczema

Trial Timeline

Jul 24, 2025 → May 2, 2027

NCT ID
NCT06807268

About Abrocitinib

Abrocitinib is a phase 3 stage product being developed by Pfizer for Eczema. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06807268. Target conditions include Eczema.

What happened to similar drugs?

2 of 12 similar drugs in Eczema were approved

Approved (2) Terminated (2) Active (8)
✅Pimecrolimus cream 1%NovartisApproved
✅DupilumabRegeneron PharmaceuticalsApproved
🔄Colloidal Oatmeal CreamJohnson & JohnsonPhase 3
🔄alitretinoin + PlaceboGSK plcPhase 3
❌Ruxolitinib cream + VehicleIncytePhase 3
❌Ruxolitinib cream + VehicleIncytePhase 3
🔄ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%Arcutis BiotherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT04564755Pre-clinicalCompleted
NCT05466578Pre-clinicalActive
NCT06899204Pre-clinicalRecruiting
NCT06807281Phase 3Recruiting
NCT06807268Phase 3Recruiting
NCT05721937Pre-clinicalRecruiting
NCT05689151Pre-clinicalRecruiting
NCT05391061Pre-clinicalRecruiting
NCT05038982Phase 2Completed

Competing Products

20 competing products in Eczema

See all competitors
ProductCompanyStageHype Score
1% Colloidal Oatmeal BalmJohnson & JohnsonPre-clinical
18
Colloidal Oatmeal CreamJohnson & JohnsonPhase 3
40
Pimecrolimus cream 1%NovartisApproved
43
Dupilumab + PlaceboSanofiPhase 2
31
Amlitelimab + PlaceboSanofiPhase 2
35
alitretinoin + PlaceboGSK plcPhase 3
40
DupilumabRegeneron PharmaceuticalsApproved
39
Adventan® (methylprednisolone aceponate 0,1%)BayerPhase 1
26
Ruxolitinib cream + VehicleIncytePhase 3
29
Ruxolitinib cream + VehicleIncytePhase 2
32
Ruxolitinib cream + VehicleIncytePhase 3
29
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%Arcutis BiotherapeuticsPhase 3
34
Roflumilast Cream + Vehicle creamArcutis BiotherapeuticsPhase 3
34
ARQ-151 cream 0.05%Arcutis BiotherapeuticsPhase 2
29
Roflumilast Cream 0.05% + Vehicle CreamArcutis BiotherapeuticsPhase 3
34
Roflumilast Cream 0.15% + Vehicle CreamArcutis BiotherapeuticsPhase 3
34
ARQ-151 cream 0.15% + ARQ-151 cream 0.05%Arcutis BiotherapeuticsPhase 1
23
ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle CreamArcutis BiotherapeuticsPhase 1/2
26
LAS41003 + LAS189962 + LAS189961AlmirallPhase 2
29
LAS 41002 + ActiveAlmirallPhase 2
29